BIOCRYST PHARMACEUTICALS INC (BCRX): Results of Operations and Financial Condition
BIOCRYST PHARMACEUTICALS INC (BCRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 BioCryst Reports Second Quarter 2026 Financial Results — Total net revenue of $218.3 million and ORLADEYO ® net revenue of $158.2 million — — Operating profit of $98.5 million and Non-GAAP operating profit of $113.2 million — — Maintained Full Year 2026 ORLADEYO reve
How this was made
The 30-second read
Why it matters
Traders can update models using the raised 2026 total revenue range, track pediatric ORLADEYO oral pellet launch ramp, and monitor ALPHA-ORBIT enrollment completion toward Q3 2027 topline.
Market read
The filing combines a guidance raise with concrete commercialization and clinical execution milestones, creating actionable updates for revenue and probability-weighted pipeline expectations.
What to watch
ORLADEYO oral pellet shipments are early (started week of Aug. 3) and prescription approvals are still ramping; execution risk in pediatric uptake could temper follow-through.
BioCryst Reports Second Quarter 2026 Financial Results — Total net revenue of $218.3 million and ORLADEYO ® net revenue of $158.2 million — — Operating profit of $98.5 million and Non-GAAP operating profit of $113.2 million — — Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $690 million to $715 million
Revenue increased +34% y-o-y, GAAP operating profit reached $98.5 million, non-GAAP operating profit was $113.2 million, and the company raised full-year total revenue guidance to $690 million to $715 million while maintaining ORLADEYO guidance.
Actuals vs. the company’s prior outlook
from its previous release| Metric | Guided | Reported | Verdict |
|---|---|---|---|
| ORLADEYO revenue | $625 million to $645 million | $158.2 million | n/a |
| Total revenue | $635 million to $660 million | $218.3 million | n/a |
| Non-GAAP operating expense | $450 million to $470 million | $105,093 | n/a |
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenuesGAAP | $218.3 million | – | +34% y-o-y |
| ORLADEYO revenueGAAP | $158.2 million | – | +1% y-o-y |
| ORLADEYO revenue, comparable basis excluding European revenuenon-GAAP | $158.2 million | – | +10% y-o-y on a comparable basis excluding European revenue |
| License and other revenuesGAAP | $60,048 | – | – |
| Cost of product salesGAAP | $3,840 | – | – |
| Research and developmentGAAP | $51,969 | – | – |
| Research and development expenses, excluding stock-based compensation expensenon-GAAP | $46.5 million | – | +37% y-o-y |
| Selling, general and administrativeGAAP | $63,976 | – | – |
| Sales and marketing expenses, excluding stock-based compensation expensenon-GAAP | $33.9 million | – | -26% y-o-y |
| Sales and marketing expenses, excluding stock-based compensation expense, comparable basis excluding European sales and marketing expensesnon-GAAP | $33.9 million | – | +2% y-o-y on a comparable basis excluding European sales and marketing expenses |
| General and administrative expenses, excluding stock-based compensation expensenon-GAAP | $20.8 million | – | -30% y-o-y |
| General and administrative expenses, excluding stock-based compensation expense, comparable basis excluding European general and administrative expenses and transaction-related costsnon-GAAP | $20.8 million | – | -2% y-o-y on a comparable basis excluding European general and administrative expenses and transaction-related costs |
| Total operating expensesGAAP | $119,785 | – | – |
| Total operating expensesnon-GAAP | $105,093 | – | – |
| Income from operationsGAAP | $98,465 | – | – |
| Income from operationsnon-GAAP | $113,157 | – | – |
| Interest incomeGAAP | $2,434 | – | – |
| Interest expenseGAAP | $(21,712) | – | – |
| Foreign currency gains (losses), netGAAP | $27 | – | – |
| Other income (expense), netGAAP | $260 | – | – |
| Total other expense, netGAAP | $(18,991) | – | – |
| Income before income taxesGAAP | $79,474 | – | – |
| Income tax expenseGAAP | $1,079 | – | – |
| Net incomeGAAP | $78,395 | – | – |
| Net income per common share, basicGAAP | $0.31 | – | – |
| Net income per common share, dilutedGAAP | $0.30 | – | – |
| Weighted average shares of common stock outstanding, basicGAAP | 254,481 | – | – |
| Weighted average shares of common stock outstanding, dilutedGAAP | 265,165 | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| ORLADEYONew patient prescriptions maintained momentum in Q2 2026. Initial product shipments of ORLADEYO oral pellets to patients began the week of August 3. | $158.2 million | – | +1% y-o-y; +10% y-o-y on a comparable basis excluding European revenue |
| License and other revenuesThe company recognized $55.7 million of revenue related to the licensing agreement with an Irish affiliate of Neopharmed Gentili for exclusive rights to commercialize navenibart in Europe. | $60,048 | – | – |
Full Year 2026 outlook
- RevenueTotal revenue of $690 million to $715 million; global net ORLADEYO revenue of $625 million to $645 million
- Operating expensesNon-GAAP operating expenses, excluding stock-based compensation, restructuring, and transaction-related costs, of $420 million to $440 million
- NoteThe company is eligible to receive up to $275.0 million in future regulatory and sales milestone payments and tiered royalties on net sales ranging from 18% to 30%.
- NoteTop-line results from both navenibart doses are expected in Q3 2027.
- NoteThe company expects to report data from Part 4 of the BCX17725 Phase 1 trial by the end of 2026.
What drove it
- Total revenues were supported by $55.7 million of recognized revenue from the navenibart European-rights licensing agreement.
- New patient prescriptions maintained momentum in Q2 2026, driving ORLADEYO revenue of $158.2 million.
- Initial ORLADEYO oral-pellet shipments to pediatric patients began the week of August 3.
- 47 prescriptions for ORLADEYO oral pellets have been written year-to-date. Over half have completed the prior authorization process and have a high approval rate.
- Patient enrollment in the ALPHA-ORBIT pivotal study of navenibart was completed in June.
- The company discontinued internal discovery programs and plans to close its Birmingham facility by the end of 2026 to prioritize external innovation and align its cost structure.
Concerns
- Reported ORLADEYO revenue increased only +1% y-o-y, with the higher +10% comparable growth excluding European revenue.
- The quarter's total revenue included $55.7 million recognized from the navenibart European-rights licensing agreement, while the balance of the $70.0 million upfront consideration is to be recognized over the next few years.
- Interest expense was $(21,712) and the company reported a $395,400 secured term loan and a $426,789 royalty financing obligation at June 30, 2026.
- For the six months ended June 30, 2026, the company reported a GAAP net loss of $(643,417), including $697,761 of acquired in-process research and development related to navenibart.
- The company cited uncertainty around the timing and costs of closing the Birmingham research facility and winding down internal discovery programs.
What to watch
- Execution of the CareMed transition, which is expected to become the sole source specialty pharmacy for ORLADEYO shipments to patients beginning in Q3 2026.
- Launch progress for ORLADEYO oral pellets in pediatric hereditary angioedema, including prescription conversion through prior authorization.
- Full-year delivery against global net ORLADEYO revenue guidance of $625 million to $645 million and total revenue guidance of $690 million to $715 million.
- Delivery of non-GAAP operating expenses of $420 million to $440 million following the discontinuation of internal discovery programs and planned Birmingham facility closure.
- Top-line results from the every-three-month and every-six-month navenibart doses in Q3 2027.
- Data from Part 4 of the BCX17725 Phase 1 trial by the end of 2026.
Balance sheet and cash flow
- Cash, cash equivalents and investments were $352,573 at June 30, 2026, compared with $335,911 at December 31, 2025.
- Restricted cash was $1,412 at June 30, 2026, compared with $1,601 at December 31, 2025.
- Cash, cash equivalents, restricted cash and investments totaled $354.0 million at June 30, 2026.
- Receivables were $110,757 at June 30, 2026, compared with $106,818 at December 31, 2025.
- Total assets were $557,851 at June 30, 2026, compared with $514,158 at December 31, 2025.
- Secured term loan was $395,400 at June 30, 2026.
- Royalty financing obligation was $426,789 at June 30, 2026, compared with $465,688 at December 31, 2025.
- Accumulated deficit was $(2,149,596) at June 30, 2026, compared with $(1,506,179) at December 31, 2025.
- Stockholders’ deficit was $(454,289) at June 30, 2026, compared with $(119,153) at December 31, 2025.
- The company generated positive cash flow during Q2 2026 even when excluding the upfront consideration received from the navenibart licensing agreement.
Analysis
BioCryst reported a strong second quarter, with GAAP total revenues of $218.3 million, up +34% y-o-y. ORLADEYO revenue was $158.2 million, up +1% y-o-y, while comparable growth excluding European revenue was +10% y-o-y. The revenue mix also included $55.7 million recognized from the navenibart European-rights licensing agreement, contributing to $60,048 of license and other revenues.
Profitability improved materially. GAAP operating profit was $98.5 million, compared with $29.8 million in the prior-year quarter, and non-GAAP operating profit was $113.2 million, compared with $60.9 million. Total GAAP operating expenses declined to $119,785 from $133,567, despite research and development expense increasing to $51,969 from $43,386. The increase in research and development expense was primarily tied to the navenibart ALPHA-ORBIT study following the Astria acquisition.
The company reported positive cash flow in Q2 2026 even excluding the licensing upfront consideration, and cash, cash equivalents, restricted cash and investments totaled $354.0 million at June 30, 2026. The balance sheet also included a $395,400 secured term loan and a $426,789 royalty financing obligation. For the six months ended June 30, 2026, the GAAP loss from operations was $(603,133), reflecting $697,761 of acquired in-process research and development related to navenibart.
Management maintained full-year global net ORLADEYO revenue guidance of $625 million to $645 million and raised total revenue guidance to $690 million to $715 million from $635 million to $660 million. It also improved full-year non-GAAP operating expense guidance to $420 million to $440 million from $450 million to $470 million, following the decision to discontinue internal discovery programs and close the Birmingham facility by the end of 2026. Execution points include the Q3 transition to CareMed as ORLADEYO's sole source specialty pharmacy, the pediatric oral-pellet launch, BCX17725 data by the end of 2026, and navenibart top-line results in Q3 2027.
Management, verbatim
We were pleased to deliver strong revenue growth and positive free cash flow again in the second quarter, reflecting our continued focus on expanding the reach of ORLADEYO while advancing our prioritized pipeline programs.
Charlie Gayer, President and Chief Executive Officer of BioCryst
Across our pipeline, we completed enrollment in our pivotal navenibart trial and continued to advance BCX17725 toward early clinical data in patients by year-end.
Charlie Gayer, President and Chief Executive Officer of BioCryst
Building on this momentum, we remain focused on cost discipline while directing our capital and energy toward opportunities where we can have the greatest impact.
Charlie Gayer, President and Chief Executive Officer of BioCryst
Not in the filing
stated, not guessed- Gross profit and gross margin were not reported.
- Operating cash flow amount was not reported.
- Free cash flow amount was not reported.
- Capital expenditures were not reported.
- GAAP and non-GAAP tax rates were not reported.
- Non-GAAP net income and non-GAAP earnings per share were not reported.
- Dividend and share-repurchase activity were not reported.
- Prior-quarter comparisons were not reported for the presented quarterly financial metrics.
- Debt maturities, interest rates, and total debt were not reported.
- Revenue guidance comparisons to actual quarterly results are not applicable because the guidance is for the full year.
- Prior full-year ORLADEYO guidance was presented as unchanged, but a separate May 6, 2026 numeric ORLADEYO guidance range was not printed in the guidance comparison table.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is BioCryst’s SEC Form 8-K with Q2 2026 financial results and business updates, including ORLADEYO commercialization progress and pipeline trial milestones.
Ticker impact
BioCryst reported Q2 2026 results and raised full-year 2026 total revenue guidance to $690M-$715M while maintaining ORLADEYO revenue guidance.
Likely positive bias for the stock into the next earnings cycle, with upside sensitivity to ORLADEYO prescription growth and pediatric launch execution.
The filing includes multiple fresh, decision-relevant datapoints: Q2 revenue and operating profit, raised total revenue outlook, start of pediatric oral pellet shipments, and completion of pivotal enrollment with a stated Q3 2027 topline timeline.
Market effects
Reinforces investor appetite for rare-disease commercial launches and pipeline execution in plasma kallikrein inhibitor franchises.
Limited direct regional read-through beyond Europe licensing economics for navenibart.
Global revenue guidance update and Europe commercialization licensing can affect expectations for cross-region rare-disease revenue mix.
Counterpoint
Raised total revenue guidance may be partially offset by higher R&D spend and milestone/royalty timing, so near-term upside could be less than it appears on headline guidance.
Key entities
- issuerBioCryst Pharmaceuticals, Inc.
Nasdaq-listed company reporting Q2 2026 results, ORLADEYO pediatric launch progress, and updated 2026 revenue guidance.
- productORLADEYO
BioCryst’s hereditary angioedema therapy; oral pellet shipments to pediatric patients began Aug. 3, 2026.
- clinical_programnavenibart (ALPHA-ORBIT)
Investigational long-acting plasma kallikrein inhibitor; ALPHA-ORBIT enrollment completed, topline expected Q3 2027.
- partnerCareMed
New commercial pharmacy partner for ORLADEYO shipments, becoming sole specialty pharmacy source beginning Q3 2026.
- licensing_counterpartyNeopharmed Gentili (Irish affiliate)
Partner in a licensing agreement granting exclusive European commercialization rights for navenibart.
